论文部分内容阅读
用ELISA法检测非甲非乙型肝炎病人血清抗c100-3的阳性率为60～80%,仍有20～30%为阴性。在抗c100—3阴性的患者似乎有抗HCV的其他结构和非结构蛋白的抗体。为此,作者改用第二代ELISA方法和重组免疫印迹试验(RIBA)来检测血清中HCV基因的核壳体区(c22—3)和NS_3/NS_4(c33 c,c200)表达产物的抗体。作者用三种方法检测313例HCV感染高危人群370份血清标本和170例低危人群的184份血清标本。高危人群指急慢性HCV感染。原发性肝癌、静脉药瘾者和血液透析病人;低危人群指甲型或乙型肝炎患者、原发性胆汁性肝硬化、酒
The positive rate of serum anti-c100-3 in non-A non-B hepatitis patients detected by ELISA was 60-80%, and 20-30% were still negative. Patients with anti-c100-3 negative appear to have antibodies against other structural and non-structural proteins of HCV. To this end, the authors used the second generation ELISA method and recombinant immunoblot assay (RIBA) to detect antibodies to the expression products of the core-shell region (c22-3) and NS_3 / NS_4 (c33c, c200) of the HCV gene in serum. The authors used three methods to detect serum samples of 370 sera from 313 HCV-infected high-risk populations and 170 sera from low-risk populations. High-risk groups refer to acute and chronic HCV infection. Primary liver cancer, intravenous drug addicts and hemodialysis patients; low-risk groups of patients with nails or hepatitis B, primary biliary cirrhosis, alcohol